

Silvia C W Ling

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2269698/publications.pdf>

Version: 2024-02-01

23
papers

331
citations

1163117

8
h-index

1199594

12
g-index

23
all docs

23
docs citations

23
times ranked

776
citing authors

#	ARTICLE	IF	CITATIONS
1	Weekly cyclophosphamide, subcutaneous bortezomib and dexamethasone (CyBORd) for initial treatment of transplant-eligible patients with multiple myeloma: experience of two transplant centres. <i>Bone Marrow Transplantation</i> , 2021, 56, 738-740.	2.4	1
2	Bone Targeted Therapies. Resistance To Targeted Anti-cancer Therapeutics, 2021, , 105-127.	0.1	0
3	Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia. <i>Internal Medicine Journal</i> , 2021, 51, 1707-1712.	0.8	1
4	The Role of Chaperone-Mediated Autophagy in Bortezomib Resistant Multiple Myeloma. <i>Cells</i> , 2021, 10, 3464.	4.1	11
5	Comparing the area under the curve and peak height methods in the calculation of FLT3–ITD allelic ratio. <i>International Journal of Laboratory Hematology</i> , 2020, 42, e234-e236.	1.3	0
6	Weekly Cyclophosphamide, Subcutaneous Bortezomib and Dexamethasone (CyBORd) for Initial Treatment of Transplant Eligible Patients with Multiple Myeloma: Experience of Two Transplant Centres. <i>Blood</i> , 2020, 136, 42-43.	1.4	0
7	In Vivo Assessment of Intracellular Dynamics Comparing Injection Versus Oral Azacitidine in a Phase IIb Investigator Initiated Clinical Trial. <i>Blood</i> , 2019, 134, 4247-4247.	1.4	0
8	Endoplasmic reticulum stress in the development of multiple myeloma and drug resistance. <i>Clinical and Translational Immunology</i> , 2018, 7, e1007.	3.8	74
9	The prognostic value of 18-FDG positron emission tomography in T cell non-Hodgkin lymphoma. <i>Blood Cancer Journal</i> , 2017, 7, e556-e556.	6.2	2
10	A quality assurance project for the molecular diagnosis of myeloproliferative neoplasms. <i>Pathology</i> , 2017, 49, S62.	0.6	0
11	Validation of cebpa mutation testing for use in a clinical setting. <i>Pathology</i> , 2017, 49, S109.	0.6	0
12	PIKK of the pick: the role of smg1 and atm in b cell lymphoproliferative disorders. <i>Pathology</i> , 2017, 49, S110.	0.6	0
13	TET2 mutations in myelodysplastic syndromes (MDS). <i>Pathology</i> , 2017, 49, S110.	0.6	0
14	Bisphosphonate guidelines for treatment and prevention of myeloma bone disease. <i>Internal Medicine Journal</i> , 2017, 47, 938-951.	0.8	19
15	The unfolded protein response in bortezomib resistant myeloma cells. <i>Pathology</i> , 2016, 48, S73-S74.	0.6	0
16	The role of SMG1 expression in B cell lymphoproliferative disease. <i>Pathology</i> , 2016, 48, S74.	0.6	0
17	Wilms tumour gene 1 (WT1) mutations in acute myeloid leukemia (AML). <i>Pathology</i> , 2016, 48, S100.	0.6	0
18	Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response. <i>Blood Cancer Journal</i> , 2016, 6, e432-e432.	6.2	19

#	ARTICLE	IF	CITATIONS
19	Molecular mechanisms in multiple myeloma drug resistance. <i>Journal of Clinical Pathology</i> , 2016, 69, 97-101.	2.0	51
20	Intravenous immunoglobulin induces short-term reversal of drug-induced autoimmune neutropenia. <i>Transfusion Medicine</i> , 2015, 25, 347-348.	1.1	5
21	The prognostic value of mid- and post-treatment [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in indolent follicular lymphoma. <i>Annals of Nuclear Medicine</i> , 2014, 28, 805-811.	2.2	22
22	Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. <i>Haematologica</i> , 2012, 97, 64-72.	3.5	109
23	Transformation and progression of Waldenström's macroglobulinemia following cladribine therapy in two cases: natural evolution or iatrogenic causation?. <i>American Journal of Hematology</i> , 2006, 81, 110-114.	4.1	17